Basket | Login


SS4 The EADC (European Alzheimer Disease Consortium)

Detailed programme and abstracts

SS4. The EADC (European Alzheimer Disease Consortium) - achievements and currently projects (Wednesday 2 Nov, 10.30 - 12.00)


The EADC is a fully functional network of European centres of excellence working in the field of Alzheimer's Disease research and care. It consists of over 60 European centres of clinical and biomedical research excellence working in the field of clinical research on Alzheimer’s disease and related dementias. Generally, specific funded and non-funded research projects to increase knowledge on diagnosis and treatment of Alzheimer‘s disease, and actions to increase standardization and harmonization of data collection and data analysis are the focus of our work.

Since ist foundation in 2000,  over 20 large pan-European multi-center and multi-disciplinary research studies have been carried out. Funding has been obtained by the different framework programs of the European Commission, and the The EU Joint Programme – Neurodegenerative Disease Research, which supported the e.g. ICTUS, DESCRIPA, EDAR, BIOMARK-APD studies. The overview on the EADC will be presented by its chairman Bengt Winblad, Stockholm, Sweden.

The newly initiated project on subjective cognitive decline (SCD) “Euro-SCD” (funded by EU-JPND) is directed by Frank Jessen, Cologne, Germany. It aims at comparing memory clinic SCD samples with regard to the prevalence of preclinal Alzheimer’s Disease and will identify characteristics for predicting AD from patients with SCD. Comparison of AD biomarker profiles in SCD will be done across memory clinics, centralized CSF biomarker profiles will be determined (tau, pTau, Aβ42, ratio).

The ongoing EADC-PET project (EAPP – The European Alzheimer’s Disease Consortium PET project) is a spontaneously initiated multicentric study, which is directed by Flavio M. Nobili, Genova, Italy. The project aims at sharing Amyloid-PET, MRI, neuropsychological, genetic, EEG and clinical information of patients with amnestic Mild Cognitive Impairment (aMCI) and matched healthy controls. Information is uploaded in a safe FTP facility on the server of University of Genoa and data are analyzed centrally.

The pathologically phosphorylated Tau protein in the brain in Alzheimer’s disease has be identified recently as a target for therapeutic interventions. In comparison to beta-amyloid protein, targeting the Tau protein is a lot more difficult and potentially harmful. Several industry-sponsored clinical trials in phase I and II of drug development are ongoing presently and several of the EADC Centers are engaging in these clinical trials. Patricia Mecocci, Perugia, Italy, will present the background of Tau-directed interventions and outline the status of the ongoing clinical trials.



Last Updated: Tuesday 10 January 2017


  • Acknowledgements

    The 26th AE Conference in Copenhagen received funding under an operating grant from the European Union’s Health Programme (2014-2020). Alzheimer Europe and Alzheimerforeningen gratefully acknowledge the support of all conference sponsors.
  • European Union
  • Roche